Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Clinical Trial
    In-Person

    A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)

    What is this Study about?

    The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.

    Eligibility Criteria

    Male or female participants aged 50 years of age
    Has a history of previous clinical intracerebral hemorrhage.
    Has probable CAA.

    Recruitment End Date

    Find Out More
  • Observational Study
    In-Person

    Toward Digital Phenotyping of Healthy and Pathological Cognitive Aging

    What is this Study about?

    This study investigates whether digital activity data collected from wearable and mobile devices can be used to understand changes in cognitive functioning associated with aging and neurological conditions. Participants’ daily movement patterns and activity behaviors will be monitored using advanced tracking technology that collects detailed spatial and temporal data. Researchers will analyze these patterns using computational methods to identify digital markers associated with cognitive functioning. 

    Eligibility Criteria

    You are eligible to participate if you are 60 years or older, have a confirmed diagnosis of Alzheimer’s disease, remain relatively independent in your day-to-day life, are able and willing to wear digital activity tracking technology to monitor daily activity patterns, and are able to provide informed consent and participate in study procedures. You are also eligible to participate if you are a partner/caregiver as a healthy control. 

    Recruitment End Date

    Find Out More